Guerbet : Résultat FY 2023 : en avance sur le plan et la guidance 2024 apparait différente
>EBITDA supérieur aux attentes - L’EBITDA 2023 a atteint 98,8 M€, +4% (Css : 88 M€e). Le RN ressort à 22 M€ vs -41 M€ fin 2022 (Css : 9,8 M€e).Le free cash-flow s’est établit à -65,4 M€ en 2023 ; sur le seul second semestre, il ressort en territoire positif à +6,6 M€. L’endettement net ressort à 335 M€ contre 270 M€ fin 2022.Guerbet réitère sa guidance : croissance de 8% à ptcc avec un objectif d’un taux de marge d’EBITDA ajusté à un niveau supérieur à celui...Guerbet is a French pharmaceutical group that develops, markets, and provides maintenance services for medical equipment and devices destined for diagnostic and interventional imaging. Co.'s portfolio comprises media solutions covering MRI, X-rays and products devoted to International Radiology and Theranostics and medical devices. Co. organizes its operation by product family covering Magnetic Resonance Imaging (MRI), X-rays (XR) and Interventional Radiology and Theranostics (IRT). The MRI family includes Dotarem® and Artirem®; Co.'s X-ray product family includes Xenetix®, Optiray®/Optiject®, Oxilan®, and Telebrix®; and the IRT product family has Lipiodol®, Bleu Patente V and Hexabrix®.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.